Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Innovative strategies to increase engraftment of engineered hematopoietic stem cells and bypass genotoxic conditioning, toward the next-generation gene therapy

Project description

Towards safer gene therapy procedures

Gene therapy for haematopoietic malignancies or inherited haematopoietic diseases entails the ex vivo genetic manipulation of haematopoietic stem or progenitor cells, which are reinfused back into the patient. The concept is that these cells will attach to the bone marrow and reconstitute a healthy haematopoietic and immune system. The scope of the EU-funded IMPROVING-GT project is to address the toxicities associated with the required bone marrow conditioning and the mobilisation of haematopoietic progenitors, which reduce the cells’ reconstitution potential. Researchers will identify milder myeloablative and mobilisation regimens with an ultimate goal to reduce toxicity and improve patients’ clinical outcome.

Objective

Hematopoietic stem/progenitor cell gene therapy (HSPC-GT) refers to the transfer of nucleic acids into HSPCs, to either add a new copy of a “healthy” gene or to correct a mutated gene. HSPC-GT is successfully used in clinic to treat patients with hematopoietic malignancies and several inherited diseases of the hematopoietic system. Yet, its current use is accompanied by acute conditioning-related toxicities, which impose a burden on patients and limit its application to the most severe conditions. HSPC-GT requires the following steps: HSPCs are mobilized and harvested from the patient, genetically corrected ex-vivo by gene transfer or gene editing and infused back to the patient, after administration of partial or fully myeloablative conditioning to make space in the bone marrow for the modified cells. Administered HSPCs home to the bone marrow, where they engraft and reconstitute a healthy immune system, theoretically throughout life. However, two major shortcomings undermine the full therapeutic potential of HSPC-GT: (i) a decrease in short- and/or long-term engraftment potential due to the ex vivo manipulation of HSPCs and (ii) a toxicity in the hematopoietic and non-hematopoietic organs related to the conditioning regimens, which are based on cytotoxic drugs. The project IMPROVING-GT proposes to develop innovative schemes to increase engraftment and dodge genotoxic conditioning, which are some of the most coveted but still unaccomplished goals of HSPC-GT. The candidate aims to (1) increase the fitness of genetically modified HSPCs by uncovering new players of engraftment and (2) bypass the toxic conditioning requirement by exploiting enhanced mobilization reagents. IMPROVING-GT will pave the way towards non or milder genotoxic regimens, which should greatly minimize undesirable toxicity of current treatments and ameliorate patients’ outcome. Moreover, it may help broadening applications of HSPC-GT to more diseases, including patients with lower disease burden.

Fields of science (EuroSciVoc)

Keywords

Programme(s)

Topic(s)

Funding Scheme

MSCA-IF - Marie Skłodowska-Curie Individual Fellowships (IF)

See all projects funded under this funding scheme

Call for proposal

(opens in new window) H2020-MSCA-IF-2020

See all projects funded under this call

Coordinator

OSPEDALE SAN RAFFAELE SRL
Net EU contribution
€ 183 473,28
Address
VIA OLGETTINA 60
20132 Milano
Italy
Region
Nord-Ovest Lombardia Milano
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Links
Total cost
€ 183 473,28